<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0024">
 <label>24</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0024">
  <string-name>
   <surname>Xu</surname>
   <given-names>RH</given-names>
  </string-name>, 
  <string-name>
   <surname>Muro</surname>
   <given-names>K</given-names>
  </string-name>, 
  <string-name>
   <surname>Morita</surname>
   <given-names>S</given-names>
  </string-name>, et al. 
  <article-title>Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second‐line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open‐label, randomised, non‐inferiority, phase 3 trial</article-title>. 
  <source xml:lang="en">Lancet Oncol</source>. 
  <year>2018</year>;
  <volume>19</volume>(
  <issue>5</issue>):
  <fpage>660</fpage>‐
  <lpage>671</lpage>.
  <pub-id pub-id-type="pmid">29555258</pub-id>
 </mixed-citation>
</ref>
